These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

34 related articles for article (PubMed ID: 31045351)

  • 1. Combination therapy with bioengineered miR-34a prodrug and doxorubicin synergistically suppresses osteosarcoma growth.
    Zhao Y; Tu MJ; Yu YF; Wang WP; Chen QX; Qiu JX; Yu AX; Yu AM
    Biochem Pharmacol; 2015 Dec; 98(4):602-13. PubMed ID: 26518752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic Chemoimmunotherapy Augmentation via Sequential Nanocomposite Hydrogel-Mediated Reprogramming of Cancer-Associated Fibroblasts in Osteosarcoma.
    Wang H; Chen Y; Wei R; Zhang J; Zhu J; Wang W; Wang Z; Wupur Z; Li Y; Meng H
    Adv Mater; 2024 Apr; 36(15):e2309591. PubMed ID: 38113900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering small-molecule and protein drugs for targeting bone tumors.
    Wang Y; Wang C; Xia M; Tian Z; Zhou J; Berger JM; Zhang XH; Xiao H
    Mol Ther; 2024 May; 32(5):1219-1237. PubMed ID: 38449313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in Osteosarcoma.
    Panez-Toro I; Muñoz-García J; Vargas-Franco JW; Renodon-Cornière A; Heymann MF; Lézot F; Heymann D
    Curr Osteoporos Rep; 2023 Aug; 21(4):330-343. PubMed ID: 37329384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brief review: Applications of nanocomposite in electrochemical sensor and drugs delivery.
    Haq Khan ZU; Khan TM; Khan A; Shah NS; Muhammad N; Tahir K; Iqbal J; Rahim A; Khasim S; Ahmad I; Shabbir K; Gul NS; Wu J
    Front Chem; 2023; 11():1152217. PubMed ID: 37007050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydroxy- and Amino-Phosphonates and -Bisphosphonates: Synthetic Methods and Their Biological Applications.
    Kaboudin B; Daliri P; Faghih S; Esfandiari H
    Front Chem; 2022; 10():890696. PubMed ID: 35721002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Progress in Improving the Delivery Methods of Bisphosphonates in the Treatment of Bone Tumors.
    Zhong Y; Li S
    Drug Des Devel Ther; 2021; 15():4939-4959. PubMed ID: 34916778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyridazinone Derivatives Limit Osteosarcoma-Cells Growth In Vitro and In Vivo.
    Moniot A; Braux J; Bour C; Guillaume C; Lamret F; Allart-Simon I; Audonnet S; Renault S; Rédini F; Laronze-Cochard M; Sapi J; Gangloff SC; Gérard S; Velard F
    Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine-Ibandronate Conjugate Enables the Bone-Targeted Combination Therapy in Bone Cancer: Synthesis and Efficacy in Combination with Docetaxel.
    Farrell KB; Zinnen S; Thamm DH; Karpeisky A
    Bioconjug Chem; 2021 Dec; 32(12):2530-2539. PubMed ID: 34779607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polyethylenimine-Bisphosphonate-Cyclodextrin Ternary Conjugates: Supramolecular Systems for the Delivery of Antineoplastic Drugs.
    Plesselova S; Garcia-Cerezo P; Blanco V; Reche-Perez FJ; Hernandez-Mateo F; Santoyo-Gonzalez F; Giron-Gonzalez MD; Salto-Gonzalez R
    J Med Chem; 2021 Aug; 64(16):12245-12260. PubMed ID: 34369757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of a new bone tumor therapy strategy based on bifunctional biomaterials.
    Liao J; Han R; Wu Y; Qian Z
    Bone Res; 2021 Mar; 9(1):18. PubMed ID: 33727543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting anti-cancer agents to bone using bisphosphonates.
    Xing L; Ebetino FH; Boeckman RK; Srinivasan V; Tao J; Sawyer TK; Li J; Yao Z; Boyce BF
    Bone; 2020 Sep; 138():115492. PubMed ID: 32585321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 12b80 - Hydroxybisphosphonate Linked Doxorubicin: Bone Targeted Strategy for Treatment of Osteosarcoma.
    David E; Cagnol S; Goujon JY; Egorov M; Taurelle J; Benesteau C; Morandeau L; Moal C; Sicard M; Pairel S; Heymann D; Redini F; Gouin F; Le Bot R
    Bioconjug Chem; 2019 Jun; 30(6):1665-1676. PubMed ID: 31045351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I dose escalation study of 12b80 (hydroxybisphosphonate linked doxorubicin) in naturally occurring osteosarcoma.
    Boyé P; David E; Serres F; Pascal Q; Floch F; Geeraert K; Coste V; Marescaux L; Cagnol S; Goujon JY; Egorov M; Le Bot R; Tierny D
    Oncotarget; 2020 Nov; 11(46):4281-4292. PubMed ID: 33245733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen-functionalized liposomes grafted with glutathione-responsive sheddable chotooligosaccharides for the therapy of osteosarcoma.
    Yin X; Feng S; Chi Y; Liu J; Sun K; Guo C; Wu Z
    Drug Deliv; 2018 Nov; 25(1):900-908. PubMed ID: 29644882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro evaluation of a biomaterial-based anticancer drug delivery system as an alternative to conventional post-surgery bone cancer treatment.
    Bischoff I; Tsaryk R; Chai F; Fürst R; Kirkpatrick CJ; Unger RE
    Mater Sci Eng C Mater Biol Appl; 2018 Dec; 93():115-124. PubMed ID: 30274043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary osteorhabdomyosarcoma (malignant mesenchymoma) of bone: a case report and review of the literature.
    Van Dorpe J; Sciot R; Samson I; De Vos R; Brys P; Van Damme B
    Mod Pathol; 1997 Oct; 10(10):1047-53. PubMed ID: 9346186
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.